Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
about
Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South AfricaTuberculosis control: challenges of an ancient and ongoing epidemicRecent advances in the development of vaccines for tuberculosisVaccines for TB: Lessons from the Past Translating into Future PotentialsFusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primatesSafety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West AfricaTh1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85AWhole genome identification of Mycobacterium tuberculosis vaccine candidates by comprehensive data mining and bioinformatic analysesCD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination.MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategiesSafety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85AImmunization with a bivalent adenovirus-vectored tuberculosis vaccine provides markedly improved protection over its monovalent counterpart against pulmonary tuberculosisThe immunology of tuberculosis: from bench to bedside.Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.Perspectives on clinical and preclinical testing of new tuberculosis vaccines.Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein.Identification of surrogates and correlates of protection in protective immunity against Mycobacterium bovis infection induced in neonatal calves by vaccination with M. bovis BCG Pasteur and M. bovis BCG Danish.Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis.Efficacy of a vaccine formula against tuberculosis in cattle.Next generation: tuberculosis vaccines that elicit protective CD8+ T cellsVaccine against tuberculosis: what's new?Flow cytometric detection of gamma interferon can effectively discriminate Mycobacterium bovis BCG-vaccinated cattle from M. bovis-infected cattle.Vaccination of guinea pigs using mce operon mutants of Mycobacterium tuberculosis.Multi-Stage Tuberculosis Subunit Vaccine Candidate LT69 Provides High Protection against Mycobacterium tuberculosis Infection in Mice.Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety ConsiderationsTuberculosis vaccine development: Shifting focus amid increasing development challenges.Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques.Tuberculosis vaccines: current status and future prospects.Translational mini-review series on vaccines: Development and evaluation of improved vaccines against tuberculosis.CBA/J mice generate protective immunity to soluble Ag85 but fail to respond efficiently to Ag85 during natural Mycobacterium tuberculosis infection.Heterologous boost vaccines for bacillus Calmette-Guérin prime immunization against tuberculosis.The Mycobacterium bovis BCG prime-Rv0577 DNA boost vaccination induces a durable Th1 immune response in mice.Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis.Mycobacterium tuberculosis culture filtrate proteins plus CpG Oligodeoxynucleotides confer protection to Mycobacterium bovis BCG-primed mice by inhibiting interleukin-4 secretion.Characterization of W-Beijing isolates of Mycobacterium tuberculosis from the Western Cape.Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects.Mucosal vaccines: novel advances in technology and delivery.Ag85B synergizes with ESAT-6 to induce efficient and long-term immunity of C57BL/6 mice primed with recombinant Bacille Calmette-Guerin.Clinical applications of attenuated MVA poxvirus strain.
P2860
Q24647137-2940EB7F-84CA-4887-88E3-26BD8732FB20Q26206908-49C348F8-B803-4EA8-9AE7-139E25BC094EQ26796440-A6DAC390-6537-46BF-BD88-7DDDED5FF6D2Q26996673-9B2762F7-7D27-4C0D-8E3A-DC6C66A0760CQ27306708-2B529323-BB17-405E-9E78-45540C81DB81Q28473318-73B15BEF-A53A-4DCF-860A-957EBC2E8D3CQ28740954-5C4FBA88-6370-4C67-8AAB-2A7164F59084Q31156691-59DA0EF8-13A6-4532-A8BC-983E934DECADQ33428562-784F0B06-3D95-435D-A614-42BCFA04B550Q33430265-E1F259FE-3B73-4480-A60F-83D0C0689209Q33440600-6165BE07-CD11-4537-A9EE-85DBFAFD3B3CQ33468451-72330068-0C33-42F0-ADE9-E14B2F1E882DQ33713700-68A77D58-4E10-49ED-AC31-7D0FA67D9E32Q33777367-FD9DDA25-4F1F-42DF-8FC7-B3F29AECE065Q33807147-E96103CA-8EC2-4F68-87D6-8F3D616F6FBEQ34189865-D8CEF6F1-2340-4BA9-A2C0-567FAF0CF1C8Q34726923-1F4F05AC-B974-455E-94AA-DA5FF2A2A8FEQ34739101-F8EE6B9C-B3EB-49BE-A810-30A41222AB5DQ34975770-53F22BF8-C96B-411B-81AC-C0094CAB6F29Q35034673-410BCDD2-8D59-4315-9DDB-0DEDDAA923C2Q35099708-02523291-6F66-406F-862A-6E60FA2E107DQ35101472-ED487018-D727-45E3-9823-0C8E833F87DFQ35216135-04097170-CABD-472F-AEB0-A01CD7624666Q35220322-A7237FDA-A9DD-4DFF-AF59-9708737DC84BQ35670390-6300A71E-6B7D-4C90-822E-B4457F56565DQ35826779-FD1C65AF-0F27-4D6B-9D07-F7D8369D4FDBQ36256304-55EE3DB3-7BB9-4DC2-BA69-C1892D3C5E2EQ36397581-B0EDB7B9-4BF3-4C24-990D-B21C8C289730Q36458393-6EA42F9F-5CE0-430A-814B-A2A89234CB44Q36736465-A72EC338-1ED4-4F22-B377-F37DB4CD6C3BQ36811028-62906E1E-24B5-49E2-90E6-6223D09096DCQ36899073-C84DE074-6B1A-4469-932E-FF1C640A4A06Q36949611-61E65499-CF8E-4514-923D-80DB517EEA6AQ37274874-183C50D8-5FBA-4413-BB66-857F38E1C620Q37451207-D0CC934B-FC0E-48DF-BA0E-88F7AF71866DQ37455406-15D8ADEA-F1FD-4110-A2CF-B58A9B7EACE6Q37461371-CC161066-C506-470A-AF4E-76797C358C9DQ37559647-7CDE495C-9DC6-4609-9AE8-EC7C4A205ADAQ37594228-70466523-6D83-4D7D-8562-BD6642048C07Q38156198-98D3D484-9BEB-4D76-9CB8-2272B2D95AD9
P2860
Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Boosting BCG with MVA85A: the ...... berculosis in clinical trials.
@ast
Boosting BCG with MVA85A: the ...... berculosis in clinical trials.
@en
type
label
Boosting BCG with MVA85A: the ...... berculosis in clinical trials.
@ast
Boosting BCG with MVA85A: the ...... berculosis in clinical trials.
@en
prefLabel
Boosting BCG with MVA85A: the ...... berculosis in clinical trials.
@ast
Boosting BCG with MVA85A: the ...... berculosis in clinical trials.
@en
P2093
P50
P1433
P1476
Boosting BCG with MVA85A: the ...... berculosis in clinical trials.
@en
P2093
Ansar A Pathan
Clare R Sander
Nilu P Goonetilleke
P356
10.1016/J.TUBE.2004.09.015
P577
2005-01-21T00:00:00Z